Which of the following art is a fusion inhibitor?
**Core Concept:** Fusion inhibitors are a class of antiretroviral medications used to treat HIV infections, specifically targeting the viral entry into host cells. They work by blocking the interaction between the viral envelope glycoprotein gp41 and the host cell receptor, preventing the fusion of viral and cellular membranes.
**Why the Correct Answer is Right:** Dolutegravir (DTG) is a potent and highly selective integrase strand-transcriotase inhibitor (INSTI) used in the treatment of HIV. It works by inhibiting the integration of the viral DNA into the host cell genome, thereby preventing the replication of the virus. Unlike other INSTIs, DTG does not require the presence of reverse transcriptase or protease inhibitors for its effectiveness.
**Why Each Wrong Option is Incorrect:**
A. Entry inhibitors (e.g., enfuvirtide) are wrong because they target the viral envelope glycoprotein gp41 and the host cell receptor, whereas DTG is an integrase inhibitor.
B. Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs, NNRTIs, and PI) are incorrect because these classes of drugs inhibit viral replication at different stages (reverse transcriptase, protease, and integrase, respectively), while DTG is a fusion inhibitor.
C. Protease inhibitors (PIs) are incorrect because they block viral protease activity, whereas DTG is an integrase inhibitor.
**Clinical Pearl:**
Dolutegravir is a cornerstone of modern HIV treatment regimens, combining high efficacy, low toxicity, and once-daily dosing. Its unique mechanism of action allows for simplified treatment regimens, reducing pill burden and improving patient adherence.
**Correct Answer:** Dolutegravir (DTG) is a potent integrase strand-transcriptase inhibitor (INSTI) used in the treatment of HIV. It is a fusion inhibitor, working by inhibiting the integration of the viral DNA into the host cell genome, thereby preventing the replication of the virus. DTG's unique mechanism of action allows for simplified treatment regimens, improving patient adherence and overall HIV treatment outcomes.